[1]Matteelli A,Sulis G,Capone S,et al.Tuberculosis elimination and the challenge of latent tuberculosis[J].Presse Medicale,2017,46(2 Pt 2):e13-e21.
[2]Houben RM,Dodd PJ.The global burden of latent tuberculosis infection:A re-estimation using mathematical modelling[J].PLoS Med,2016,13(10):e1002152.
[3]Gao L,Lu W,Bai L,et al.Latent tuberculosis infection in rural China:Baseline results of a population-based,multicentre,prospective cohort study[J].Lancet Infect Dis,2015,15(3):310-319.
[4]Pan D,Pan M,Xu YM.miR-29a expressions in peripheral blood mononuclear cell and cerebrospinal fluid:Diagnostic value in patients with pediatric tuberculous meningitis[J].Brain Research Bulletin,2017,130:231-235.
[5]Schmitt MJ,Margue C,Behrmann I,et al.MiRNA-29:A microRNA family with tumor-suppressing and immune-modulating properties[J].Curr Mol Med,2013,13(4):572-585.
[6]Wu Z,Huang X,Huang X,et al.The inhibitory role of miR-29 in growth of breast cancer cells[J].Journal of Experimental & Clinical Cancer Research,2013,32(1):98.
[7]Wang MJ,Li L,Hu YW,et al.Analysis on the expression level of ADAM17 in lung adenocarcinoma with pleural metastasis and tuberculous pleurisy[J].Modern Oncology,2017,25(23):3764-3766.[王美钧,李莲,呼延武,等.ADAM17在肺腺癌胸膜转移性胸膜炎与结核性胸膜炎鉴别诊断中的意义[J].现代肿瘤医学,2017,25(23):3764-3766.]
[8]Zhang QD,Wang PP,Feng XP.Expression of miR-204 in ovarian cancer and its role in ovarian cancer cells proliferation and invasion[J].Modern Oncology,2017,25(16):2632-2635.[张青冬,汪萍萍,冯晓萍.miR-204 在卵巢癌中的表达及对卵巢癌细胞增殖、侵袭的影响[J].现代肿瘤医学,2017,25(16):2632-2635.]
[9]Sheervalilou R,Ansarin K,Fekri Aval S,et al.An update on sputum microRNAs in lung cancer diagnosis[J].Diagn Cytopathol,2016,44(5):442-449.
[10]Lv Y,Guo S,Li XG,et al.Sputum and serum microRNA-144 levels in patients with tuberculosis before and after treatment.Sputum and serum microRNA-144 levels in patients with tuberculosis before and after treatment[J].Int J Infect Dis,2016,43:68-73.
[11]Yi Z,Fu Y,Ji R,et al.Altered microRNA signatures in sputum of patients with active pulmonary tuberculosis[J].PloS One,2012,7(8):e43184.
[12]Ortiz-Quintero B.Cell-free microRNAs in blood and other body fluids,as cancer biomarkers[J].Cell Proliferation,2016,49(3):281-303.
[13]Nymoen DA,Slipicevic A,Holth A,et al.MiR-29a is a candidate biomarker of better survival in metastatic high-grade serous carcinoma[J].Human Pathology,2016,54:74-81.
[14]Zhang M,Guo W,Qian J,et al.Negative regulation of CDC42 expression and cell cycle progression by miR-29a in breast cancer[J].Open Medicine,2016,11(1):78-82.
[15]Fu Y,Yi Z,Wu X,et al.Circulating microRNAs in patients with active pulmonary tuberculosis[J].J Clin Microbiol,2011,49(12):4246-4251.
[16]Wang C,Yang S,Liu CM,et al.Screening and identification of four serum miRNAs as novel potential biomarkers for cured pulmonary tuberculosis[J].Tuberculosis,2018,108:26-34.